FDA Decision on MHT Warnings – A Live EMAS Roundtable

A timely expert discussion on the FDA’s removal of Black Box warnings from menopausal hormone therapy. EMAS leaders reflect on the impact of WHI, what the evidence really shows, and how menopause care is evolving.

With Petra StuteAngela DeRosa, Elena Armeni and Dorenda van Dijken

→ Read the EMAS official statement


You may also like